NEW YORK, November 5, 2025 – Teva Pharmaceutical Industries (TEVA) reported third-quarter earnings that topped Wall Street estimates, driven by strong sales of its branded drug portfolio. The Israeli drugmaker’s performance signals a continued turnaround story as it leverages its innovative medicines to offset generic drug pricing pressures.
Key Takeaways
- Adjusted earnings of 78 cents per share beat expectations
- Revenue rose 3% year-over-year to 4.5 billion
- Austedo sales momentum drives raised 2025 guidance
Market Reaction & Context
Teva reported adjusted earnings of 78 cents per diluted share for the July-September quarter, up from 69 cents a year earlier 1. Revenue increased 3% to 4.5 billion, or 1% in local currency terms, as the company’s trio of branded drugs continued to gain market traction 2.
The pharmaceutical sector has faced headwinds from generic drug pricing pressure and regulatory scrutiny. However, Teva’s branded portfolio, particularly its Austedo treatment for Huntington’s disease and tardive dyskinesia, has provided a growth engine that differentiates it from pure-play generic manufacturers.
Branded Drug Portfolio Drives Performance
The company’s innovative medicines segment showed particular strength, with Austedo leading the charge in sales growth 3. Strong performance from this trio of branded drugs helped offset continued pricing pressure in Teva’s generics business, which has historically been the company’s core revenue driver.
New generic drug launches also contributed to the quarter’s performance, demonstrating Teva’s ability to compete across both innovative and generic pharmaceutical markets 3. This diversified approach has become increasingly important as the company works to reduce its dependence on any single revenue stream.
Raised Guidance Signals Confidence
Management raised its 2025 outlook for both Austedo sales and non-GAAP earnings per share, reflecting confidence in the drug’s continued market penetration 2. The guidance increase suggests Teva expects the momentum in its branded portfolio to continue through the remainder of the fiscal year.
The company also addressed investor concerns about potential US tariff impacts, with management indicating they are not worried about trade policy headwinds affecting their operations 1.
Institutional Interest Grows
Phoenix Financial recently acquired more than 3.5 million additional shares of Teva in the third quarter, elevating their total stake to an estimated 834 million 6. This significant institutional investment signals growing confidence in Teva’s transformation strategy and long-term prospects.
The move by Phoenix Financial, described as an Israeli investment giant, represents one of the larger recent institutional bets on the pharmaceutical company’s turnaround narrative 8.
Looking Forward
Teva’s third-quarter results demonstrate the company’s progress in transitioning from a generic-focused business model to one that balances innovative medicines with traditional generics. The strong performance of Austedo and other branded drugs provides a foundation for sustained growth, even as the generics market remains challenging.
The raised guidance and continued institutional investment suggest confidence in Teva’s ability to execute its strategic vision through 2025 and beyond.
Not investment advice. For informational purposes only.
References
1(November 5, 2025). “Teva Pharm profit tops estimates, says not worried by US tariffs”. Reuters. Retrieved November 5, 2025.
2(November 5, 2025). “Increases 2025 Outlook for Austedo and Non-GAAP EPS”. Yahoo Finance. Retrieved November 5, 2025.
3(November 5, 2025). “Teva’s New Drug Wins Spark Growth In The US Market”. Finimize. Retrieved November 5, 2025.
4(November 5, 2025). “Teva Pharm third-quarter profit tops estimates as branded drugs gain”. MarketScreener. Retrieved November 5, 2025.
5(November 5, 2025). “Teva Pharma Surges On Its Big Sales Beat, Austedo Guidance Hike”. Investor’s Business Daily. Retrieved November 5, 2025.
6(November 5, 2025). “Did Phoenix Financial’s Big Stake Boost Just Shift Teva (TEVA…)”. Yahoo Finance. Retrieved November 5, 2025.
7(November 5, 2025). “Teva Pharmaceutical Industries (TEVA) Stock Price & Overview”. StockAnalysis. Retrieved November 5, 2025.
8(November 3, 2025). “Here’s Why This Israeli Investment Giant Is Betting 834 Million on Teva Stock”. Nasdaq. Retrieved November 5, 2025.